By the catalytic domain, PCSK9 binds to the epidermal growth factor-like repeat A domain (EGF-A) of LDL receptor (LDLR) and enhances the degradation of LDLR, which increases the serum lipid levels and accelerates the procession of atherosclerosis. The gene discussed is PCSK9; the disease is atherosclerosis.